Skip to main content
TipRanks
Go Ultimate75% OFF

Kimberly Clark (KMY) AI Stock Analysis

6 Followers
DE:KMY

Kimberly Clark

(XETRA:KMY)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong cash generationRobust operating and free cash flow gives Kimberly-Clark internal funding for brand investment, innovation, debt service, and integration costs. The strong conversion of earnings into cash provides resilience through cost pressure and supports sustained execution over the next several quarters.
Negative Factors
Elevated leverageHigh leverage leaves Kimberly-Clark with less financial flexibility and increases sensitivity to weaker operating performance, refinancing needs, and integration costs. Although management targets lower leverage, the current capital structure remains a material constraint on allocation choices.

Kimberly Clark (KMY) vs. iShares MSCI Germany ETF (EWG)

-10%-5%0%5%10%15%20%DE:KMY+18.22%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 36.39B
Dividend Yield
4.43%
Average Volume (3M)
883
Price to Earnings (P/E)
11.0
Beta (1Y)
0.22
Revenue Growth
-13.28%
EPS Growth
59.26%
Country
Germany
Employees
36,000
Sector
Consumer Defensive
Sector Strength
62
Industry
Household & Personal Products

Kimberly Clark Business Overview & Revenue Model

Company Description

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates in two segments, North America and International Personal Care. The North America segment offers disposable...

Kimberly Clark Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:0.76%|Next Earnings Date:Jan 27, 2027
Earnings Call SentimentPositive

The call was broadly optimistic, led by the completed Kenvue acquisition, strong confidence in the integration plan, on-track cost synergies, positive Kenvue brand momentum, North American tissue strength, continued productivity, and sustained investment in future growth. Offsetting challenges included North American execution and distribution issues, China diaper recovery, Kenvue skincare and oral-care weakness, elevated freight-driven inflation, and expected mid-single-digit EPS dilution in 2027. Overall, the highlights significantly outweigh the lowlights.

Positive Updates

Kenvue Acquisition Completed
Kimberly-Clark officially completed its acquisition of Kenvue, marking a major milestone in its Powering Care transformation. The company implemented the new leadership team and operating model, completed critical day-one priorities, and sequenced multi-year systems and process integration roadmaps.

Negative Updates

North American KC Soft Quarter
Management described the North American Kimberly-Clark business as having a soft quarter. Retailer inventory changes created about a 130-basis-point headwind, a major new-product launch was postponed because a new manufacturing asset did not meet desired quality levels, and club distribution changes in baby care contributed to share softness.

Company Guidance

The company maintained fiscal 2026 guidance, expecting stronger underlying business momentum, a strong global commercial agenda for the fourth quarter, incremental cost mitigating actions, and an easier comp in the fourth quarter; full-year gross inflationary impacts are projected at around $250 million, including $50 million in the second quarter and around $200 million in the second half, while gross productivity was 6.1% year to date and 5.8% for the third quarter. Pricing is expected to be relatively flat for the year, versus year-to-date pricing down about 70 basis points for the total company and 80 basis points in North America. For 2027, adjusted EPS dilution is expected to be mid-single-digit versus standalone Kimberly-Clark EPS, with amortization of intangible assets included in non-GAAP metrics, followed in 2028 by mid to high single-digit EPS growth on a compounded basis, two years versus the baseline of 2026 standalone KC; the company also expects approximately getting to about a two times leverage by the end of the second year of the transaction. Cost synergies are about $1.9 billion, with overheads optimization driving about a third, COGS closer to 40% of the overall, give or take, so between 30%-40% of the synergies, and sales and marketing and trade spend optimization comprising the third bucket; revenue synergies were $1.4 billion in revenue, $200 million in EBIT contribution net, and reinvestment of around $300 million, or close to 60% in the modeling.

Kimberly Clark Risk Analysis

Kimberly Clark disclosed 26 risk factors in its most recent earnings report. Kimberly Clark reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Kimberly Clark Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

DE:KMY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CHDCHD78Outperform$26.67B34.6618.21%1.09%1.70%2.07%
PGPG72Outperform$393.56B25.1629.55%2.55%3.52%-3.74%
CLCL67Neutral$79.23B38.721135.82%2.12%5.91%-28.30%
ULUL64Neutral$141.99B14.0758.26%3.25%-17.45%8.84%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
CLXCLX58Neutral$13.26B19.69-1920.57%4.55%6.28%-13.15%

* Consumer Defensive Sector Average

Performance Comparison

0%20%DE:KMYCHDCLXCLPGULDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:KMY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:KMYKimberly Clark99.1513.4815.73%
CHDChurch & Dwight Company113.0030.9837.77%
CLXClorox Company109.4613.1413.65%
CLColgate-palmolive Company99.6722.7129.50%
PGProcter & Gamble Company169.8028.0919.82%
ULUnilever plc66.214.857.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.